David A. Siegel Generation Bio Co. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Generation Bio Co. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 217,100 shares of GBIO stock, worth $258,349. This represents 0.0% of its overall portfolio holdings.

Number of Shares

217,100

Previous 272,000 20.18%

Holding current value

$258,349

Previous $767,000 30.12%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.16 - $3.51 $118,584 - $192,699	-54,900 Reduced 20.18%	217,100 $536,000
Q2 2024 Aug 14, 2024	SELL	$2.64 - $4.35 $162,624 - $267,960	-61,600 Reduced 18.47%	272,000 $767,000
Q1 2024 May 15, 2024	BUY	$1.73 - $4.07 $209,676 - $493,284	121,200 Added 57.06%	333,600 $1.36 Million
Q4 2023 Feb 14, 2024	BUY	$0.91 - $3.35 $177,177 - $652,245	194,700 Added 1100.0%	212,400 $350,000
Q3 2023 Nov 14, 2023	SELL	$3.65 - $6.9 $35,770 - $67,620	-9,800 Reduced 35.64%	17,700 $67,000
Q2 2023 Aug 14, 2023	BUY	$3.5 - $5.67 $6,300 - $10,206	1,800 Added 7.0%	27,500 $151,000
Q1 2023 May 15, 2023	BUY	$3.61 - $7.01 $3,249 - $6,309	900 Added 3.63%	25,700 $110,000
Q4 2022 Feb 14, 2023	SELL	$3.66 - $6.77 $45,384 - $83,948	-12,400 Reduced 33.33%	24,800 $97,000
Q3 2022 Nov 14, 2022	BUY	$4.68 - $8.34 $76,752 - $136,776	16,400 Added 78.85%	37,200 $198,000
Q2 2022 Aug 15, 2022	SELL	$4.87 - $9.41 $234,734 - $453,562	-48,200 Reduced 69.86%	20,800 $136,000
Q1 2022 May 16, 2022	SELL	$4.16 - $7.76 $37,024 - $69,064	-8,900 Reduced 11.42%	69,000 $506,000
Q4 2021 Feb 14, 2022	BUY	$5.99 - $24.97 $466,621 - $1.95 Million	77,900 New	77,900 $552,000

Others Institutions Holding GBIO

# of Institutions

Shares Held

49.6M

Call Options Held

Put Options Held

View Full List

About Generation Bio Co.

Ticker GBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,011,200
Market Cap $70.2M
Description
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was f...

More about GBIO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account